Lantern Pharma annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Lantern Pharma Depreciation & Amortization Growth & History (LTRN)
Lantern Pharma's depreciation and amortization was $17,280 for fiscal 2025.
View full Lantern Pharma company overviewLantern Pharma annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $17,280 | −$2 | −0.01% |
| 2024 | 2024-12-31 | $17,282 | $2,667 | +18.25% |
| 2023 | 2023-12-31 | $14,615 | $4,534 | +44.98% |
| 2022 | 2022-12-31 | $10,081 | $3,320 | +49.11% |
| 2021 | 2021-12-31 | $6,761 | $3,373 | +99.56% |
| 2020 | 2020-12-31 | $3,388 | $1,761 | +108.24% |
| 2019 | 2019-12-31 | $1,627 | — | — |
Lantern Pharma quarterly depreciation and amortization
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3,751 | −$750 | −16.66% |
| Q1 2026 | 2026-03-31 | $3,853 | −$721 | −15.76% |
| Q4 2025 | 2025-12-31 | $4,103 | — | — |
| Q3 2025 | 2025-09-30 | $4,102 | −$287 | −6.54% |
| Q2 2025 | 2025-06-30 | $4,501 | $243 | +5.71% |
| Q1 2025 | 2025-03-31 | $4,574 | $513 | +12.63% |
| Q3 2024 | 2024-09-30 | $4,389 | $678 | +18.27% |
| Q2 2024 | 2024-06-30 | $4,258 | $747 | +21.28% |
| Q1 2024 | 2024-03-31 | $4,061 | $643 | +18.81% |
| Q3 2023 | 2023-09-30 | $3,711 | $764 | +25.92% |
| Q2 2023 | 2023-06-30 | $3,511 | $1,126 | +47.21% |
| Q1 2023 | 2023-03-31 | $3,418 | $1,429 | +71.85% |
| Q3 2022 | 2022-09-30 | $2,947 | $1,100 | +59.56% |
| Q2 2022 | 2022-06-30 | $2,385 | $805 | +50.95% |
| Q1 2022 | 2022-03-31 | $1,989 | $646 | +48.10% |
| Q3 2021 | 2021-09-30 | $1,847 | $754 | +68.98% |
| Q2 2021 | 2021-06-30 | $1,580 | $914 | +137.24% |
| Q1 2021 | 2021-03-31 | $1,343 | $807 | +150.56% |
| Q3 2020 | 2020-09-30 | $1,093 | $631 | +136.58% |
| Q2 2020 | 2020-06-30 | $666 | — | — |
| Q1 2020 | 2020-03-31 | $536 | — | — |
| Q3 2019 | 2019-09-30 | $462 | — | — |
Lantern Pharma depreciation and amortization trends
Over the last five fiscal years, Lantern Pharma's depreciation and amortization increased from $3,388 to $17,280, a change of $13,892. The latest reported quarter, Q2 2026, shows $3,751.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lantern Pharma source filings ↗